A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary.
Alicia-Marie ConwaySimon P PearceAlexandra ClipsonSteven M HillFrancesca ChemiDan Slane-TanSaba FerdousA S Md Mukarram HossainKatarzyna KamienieckaDaniel J WhiteClaire MitchellAlastair R W KerrMatthew G KrebsGerard BradyCaroline DiveNatalie CookDominic G RothwellPublished in: Nature communications (2024)
Cancers of Unknown Primary (CUP) remains a diagnostic and therapeutic challenge due to biological heterogeneity and poor responses to standard chemotherapy. Predicting tissue-of-origin (TOO) molecularly could help refine this diagnosis, with tissue acquisition barriers mitigated via liquid biopsies. However, TOO liquid biopsies are unexplored in CUP cohorts. Here we describe CUPiD, a machine learning classifier for accurate TOO predictions across 29 tumour classes using circulating cell-free DNA (cfDNA) methylation patterns. We tested CUPiD on 143 cfDNA samples from patients with 13 cancer types alongside 27 non-cancer controls, with overall sensitivity of 84.6% and TOO accuracy of 96.8%. In an additional cohort of 41 patients with CUP CUPiD predictions were made in 32/41 (78.0%) cases, with 88.5% of the predictions clinically consistent with a subsequent or suspected primary tumour diagnosis, when available (23/26 patients). Combining CUPiD with cfDNA mutation data demonstrated potential diagnosis re-classification and/or treatment change in this hard-to-treat cancer group.
Keyphrases
- machine learning
- papillary thyroid
- end stage renal disease
- squamous cell
- dna methylation
- chronic kidney disease
- newly diagnosed
- deep learning
- ionic liquid
- big data
- childhood cancer
- pulmonary embolism
- artificial intelligence
- gene expression
- high resolution
- electronic health record
- radiation therapy
- lymph node metastasis
- patient reported outcomes
- patient reported
- replacement therapy